These are academic contact details and should not be used for clinical correspondence.
Helen Johnson (Academic)
Clinical contact information
Professor of Neurology and Neurobiology
- Head of the Division of Clinical Neurology
- Senior Wellcome Clinical Scientist
- Honorary Consultant Neurologist
- Research Fellow of Green Templeton College
Pain, channelopathy, sensation, neuroscience
My research aim is to gain a better understanding of the response of the nervous system to injury in order to develop strategies to promote peripheral nerve repair and to prevent the development of neuropathic pain. This is complementary to my clinical interest in peripheral neuropathy and pain management.
I administer a specialist neuropathy and channelopathy clinical service at the Oxford University Hospitals Foundation Trust. I employ a multi-disciplinary approach including electrophysiology, cell culture, preclinical transgenic models and transcriptional profiling as well as biomarker, psychophysical and genetic studies in patients.
This research programme is leading to a better understanding of the signaling events which lead to neuropathic pain, improved means of patient stratification and led to new drug targets which are undergoing clinical trials.
I have been involved in understanding the genetic basis of inherited painful channelopathies (for instance familial episodic pain syndrome due to TRPA1 mutations as well as rare variants in Nav1.7) and in the description and validation of novel pain mediators such as NGF and CXCL5.
I am a member of the London Pain Consortium and I lead DOLORisk a Horizon 20.20 initiative with 11 participating centres which is investigating the risk factors and determinants of neuropathic pain. Iwas awarded an honorary Skou Professorship at the University of Aarhus 2019.
Long-term tactile hypersensitivity after nerve crush injury in mice is characterized by the persistence of intact sensory axons
Kim HW. et al, (2023), Pain
Inhibition of sensory neuron driven acute, inflammatory, and neuropathic pain using a humanised chemogenetic system
Sanchez JP. et al, (2023), bioRxiv
Maximizing treatment efficacy through patient stratification in neuropathic pain trials.
Baron R. et al, (2022), Nat Rev Neurol
Investigating genotype-phenotype relationship of extreme neuropathic pain disorders in a national cohort: ’NIHR Bioresources Rare Disease – Neuropathic Pain Disorders’
THEMISTOCLEOUS A. et al, (2022), Brain Communications
Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT.
Tesfaye S. et al, (2022), Health Technol Assess, 26, 1 - 100